An Evaluation Of Allogene Therapeutics Inc (NASDAQ: ALLO) Prospects

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

ALLO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Allogene Therapeutics Inc is $480.19M. A total of 2.82 million shares were traded on the day, compared to an average of 2.74M shares.

In the most recent transaction, MESSEMER DEBORAH M. sold 18,641 shares of ALLO for 2.28 per share on Jun 18 ’24. After the transaction, the Director now owns 166,765 company shares. In a previous transaction on May 30 ’24, Humer Franz B sold 11,200 shares at 2.34 per share. ALLO shares that Director owns now total 255,253.

Among the insiders who bought shares, Belldegrun Arie acquired of 1,724,137 shares on May 16 ’24 at a per-share price of $2.90. This resulted in the Director holding 1,724,137 shares of ALLO after the transaction. In another insider transaction, Parker Geoffrey M. bought 190 shares at $3.60 per share on Jan 30 ’24. Company shares held by the CHIEF FINANCIAL OFFICER now total 819,590.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ALLO has a high of $6.05 and a low of $2.01.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $47.91M in liabilities at the time. Its Book Value Per Share was $2.71, while its Total Shareholder’s Equity was $925.20M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.42.

Most Popular

Related Posts